| Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (25543)(COMPLETED)(P05817) (NCT00212836) | Organon and Co | 2005-04-21 |
| Effects of Psychoeducation of Relatives to Patients With Serious Mental Illness (NCT00184379) | Norwegian University of Science and Technology | 2005-04-01 |
| Assertive Community Treatment (ACT) in Schizophrenia Spectrum Disorders (NCT01081418) | Universitätsklinikum Hamburg-Eppendorf | 2005-04-01 |
| The Effects of Nicotine Withdrawal on Reward Responsivity in Schizophrenia (NCT00373126) | North Suffolk Mental Health Association | 2005-04-01 |
| The Effects of Aripiprazole on the Processing of Rewards in Schizophrenia (NCT00209027) | Emory University | 2005-04-01 |
| Best Event Schizophrenia Trial--A Randomized Double-Blind Trial of Aripiprazole and Risperidone in Schizophrenia (NCT00712270) | Kettering Health Network | 2005-04-01 |
| A Study to Evaluate the Effectiveness and Safety of 3 Doses of Paliperidone Palmitate in Treating Subjects With Schizophrenia (NCT00210548) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-04-01 |
| Long-Term Efficacy and Safety of Asenapine Using Olanzapine as a Positive Control (41512)(COMPLETED)(P05784) (NCT00156091) | Organon and Co | 2005-04-01 |
| To Determine Long Term Efficacy and Safety of Asenapine in Schizophrenic Patient Population (A7501012)(COMPLETED)(P05770) (NCT00150176) | Organon and Co | 2005-04-01 |
| Dopamine Function and Reward Processing In Schizophrenia (NCT01035996) | National Institute on Drug Abuse (NIDA) | 2005-03-08 |
| Effect on Cognitive Function of a Treatment With Aripiprazole (NCT00329810) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2005-03-01 |
| Functional Neuroimaging Effects of Cognitive Remediation Training (NCT00481156) | University of Minnesota | 2005-03-01 |
| Measurement of Activity Participation for Persons With Schizophrenia Living in the Community (NCT00172731) | National Taiwan University Hospital | 2005-03-01 |
| Relapse Prevention, RoW: Study to Evaluate Prevention of Relapse in Patients in Stable Chronic Schizophrenia Receiving Either Seroquel or Placebo (NCT00228462) | AstraZeneca | 2005-03-01 |
| Effectiveness of Aripiprazole for Improving Side Effects of Clozapine in the Treatment of People With Schizophrenia (NCT00345033) | Massachusetts General Hospital | 2005-03-01 |
| Abilify Therapy for Reducing Comorbid Substance Abuse (NCT00208169) | Creighton University | 2005-03-01 |
| A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™) (NCT00216632) | Janssen Pharmaceutica N.V., Belgium | 2005-03-01 |
| Efficacy and Safety of Asenapine With Placebo and Olanzapine (41022)(P05947) (NCT00151424) | Organon and Co | 2005-02-15 |
| fMRI Study of Nicotinic Effect on Neurophysiology of Schizophrenia (NCT01046526) | National Institute on Drug Abuse (NIDA) | 2005-02-08 |
| A Study of the Efficacy (Effectiveness) of Paliperidone Palmitate in the Prevention of Recurrence of the Symptoms of Schizophrenia. (NCT00111189) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-02-01 |
| A Study to Compare the Effectiveness and Safety of Flexibly Varied Doses of Paliperidone Palmitate and Risperidone in Treating Patients With Schizophrenia (NCT00210717) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-02-01 |
| Treatment of Mania Symptoms With Drug Therapy (NCT00183443) | Palo Alto Veterans Institute for Research | 2005-02-01 |
| Diabetes Prevention Program in Schizophrenia [DPPS] (NCT00182494) | Hamilton Health Sciences Corporation | 2005-02-01 |
| Trial Evaluating Paliperidone Extended-Release (ER) Tablets Versus Placebo on Sleep in Schizophrenia Patients (NCT00105326) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-02-01 |
| A Study of QT and QTc Intervals in Patients Administered Immediate Release Paliperidone (NCT00791349) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2005-02-01 |
| Efficacy of Galantamine to Treat Schizophrenia (NCT00232349) | Seattle Institute for Biomedical and Clinical Research | 2005-02-01 |
| Efficacy and Safety Study of Aripiprazole to Treat Schizophrenia (NCT00202007) | Otsuka Beijing Research Institute | 2005-02-01 |
| Changes in Adiposity, Metabolic Measures From Atypicals to Aripiprazole (NCT00205660) | Washington University School of Medicine | 2005-02-01 |
| Functional Rehabilitation of Older Patients With Schizophrenia (NCT00237796) | US Department of Veterans Affairs | 2005-02-01 |
| D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia (NCT00237848) | Yale University | 2005-02-01 |
| Family-Directed Cognitive Adaptation Program for Individuals With Schizophrenia (NCT00434980) | Beth Israel Deaconess Medical Center | 2005-02-01 |
| An Exploratory Study on the Safety and Effectiveness of Paliperidone in Patients With Schizophrenia (NCT00257023) | Janssen Pharmaceutical K.K. | 2005-02-01 |
| Effectiveness of Antipsychotic Combination With Psychosocial Intervention on Outcome of Patients With Schizophrenia (NCT00654576) | Central South University | 2005-02-01 |
| The Immune System and Psychiatric Disorders (NCT00184418) | Norwegian University of Science and Technology | 2005-01-01 |
| Addition of Ondansetron to Ongoing Antipsychotic Treatment for Schizophrenia (NCT00149734) | University of Colorado, Denver | 2005-01-01 |
| Pregnenolone in the Management of Schizophrenia Patients (NCT00174889) | Sha'ar Menashe Mental Health Center | 2005-01-01 |
| Phase 2 Trial of a Nicotinic Agonist in Schizophrenia (NCT00100165) | University of Colorado, Denver | 2005-01-01 |
| Behavioral Treatment of Drug Abuse in Severe and Persistent Mental Illness (SPMI) Patients (NCT00295139) | University of Maryland, Baltimore | 2005-01-01 |
| Motivational Interviewing to Improve Work Outcomes in Schizophrenia (NCT00261716) | VA Office of Research and Development | 2005-01-01 |
| Maintenance of Efficacy With Risperidone Long Acting Injectable (R-LAI) in Patients With Schizophrenia or Schizoaffective Disorder (NCT01888107) | Janssen-Cilag S.p.A. | 2005-01-01 |
| Lamictal TM, Haloperidol Decanoate in Schizophrenia (NCT00947375) | Central Mental Clinic for Outpatients of Baku City | 2005-01-01 |
| Add-On Therapy to Risperidonein Schizophrenia (NCT01189006) | National Cheng-Kung University Hospital | 2005-01-01 |
| Safety Study of ACP-104: To Demonstrate the Safety, Tolerability, and Pharmacokinetics (NCT00628420) | University of Texas Southwestern Medical Center | 2005-01-01 |
| Ziprasidone for Clozapine- or Olanzapine-Associated Diabetes Mellitus (NCT00351000) | North Suffolk Mental Health Association | 2005-01-01 |
| Pilot Study of Atomoxetine To Enhance COgnition In Patients With Schizophrenia (NCT00488163) | Research Foundation for Mental Hygiene, Inc. | 2005-01-01 |
| Effect Of Talnetant Versus Risperidone Versus Placebo On Psychotic Symptoms In Schizophrenic Patients (NCT00300963) | GlaxoSmithKline | 2004-12-01 |
| Effect of Add-on Citalopram to Risperidone on Negative Symptoms in Schizophrenia (NCT00893256) | National Institute of Mental Health and Neuro Sciences, India | 2004-12-01 |
| A Study to Evaluate Treatment Adherence in Schizophrenia With Long Acting Risperidone Microspheres (e-STAR) (NCT00294008) | Janssen Korea, Ltd., Korea | 2004-12-01 |
| High Dose of Quetiapine in Treating Subjects With Treatment Refractory Schizophrenia or Schizoaffective Disorder (NCT00297947) | Manhattan Psychiatric Center | 2004-12-01 |
| Patient-Centered Medication Adherence Intervention for Schizophrenia (NCT00144027) | US Department of Veterans Affairs | 2004-12-01 |
| Study Of Talnetant Versus Placebo And Risperidone In Schizophrenia (NCT00103727) | GlaxoSmithKline | 2004-12-01 |
| Efficacy and Safety of a Long Acting Anti-Psychotic Versus Placebo in Patients With Schizophrenia (NCT00101634) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-12-01 |
| Efficacy and Safety of Asenapine Compared With Olanzapine in Patients With Persistent Negative Symptoms of Schizophrenia (A7501013)(COMPLETED)(P05771) (NCT00145496) | Organon and Co | 2004-12-01 |
| Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone (NCT00174200) | Pfizer | 2004-12-01 |
| Determining Metabolic Effects of Valproate and Antipsychotic Therapy (NCT00167934) | Washington University School of Medicine | 2004-12-01 |
| Cognitive Remediation for Schizophrenia (NCT00261794) | US Department of Veterans Affairs | 2004-11-01 |
| An Observational Study to Assess Treatment & Outcomes Data in Patients Receiving Long-Acting Injectable Risperidone (NCT00774085) | Janssen Cilag N.V./S.A. | 2004-11-01 |
| Clinical Effect Of Cross Titration Of Antipsychotics With Ziprasidone In Schizophrenia Or Schizoaffective Disorder (NCT00137020) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-11-01 |
| Cognitive Remediation for Schizophrenia (NCT00295048) | University of Maryland, Baltimore | 2004-11-01 |
| The Efficacy of Escitalopram for Negative Symptoms in Schizophrenia (NCT00148447) | BeerYaakov Mental Health Center | 2004-11-01 |
| Magnetic Stimulation as a Treatment for Auditory Hallucinations in Schizophrenia (NCT00186771) | St. Joseph's Healthcare Hamilton | 2004-11-01 |
| Immediate Release (IR) to Sustained Release (SR) Switching Study: Study of Switching From IR Seroquel to SR Seroquel in Outpatients With Schizophrenia (NCT00206128) | AstraZeneca | 2004-11-01 |
| Seroquel Switching Study: Feasibility of Switching Any Antipsychotic Treatment to Seroquel in Patients With Schizophrenia (NCT00234377) | AstraZeneca | 2004-11-01 |
| PREvent First Episode Relapse (PREFER) (NCT00220714) | State University of New York - Downstate Medical Center | 2004-11-01 |
| Valproate in Late Life Schizophrenia (NCT00194025) | University Hospitals Cleveland Medical Center | 2004-11-01 |
| Israel Multicenter D-Serine Study (IMSER) for the Treatment of Schizophrenia (NCT00138775) | Sheba Medical Center | 2004-10-01 |
| SWitching to Abilify Trial (SWAT) (NCT00304616) | Korea Otsuka Pharmaceutical Co., Ltd. | 2004-10-01 |
| Effectiveness of Pimozide in Augmenting the Effects of Clozapine in the Treatment of Schizophrenia (NCT00158223) | Icahn School of Medicine at Mount Sinai | 2004-10-01 |
| A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder (NCT00216476) | Janssen-Cilag International NV | 2004-10-01 |
| A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis (NCT00246259) | Janssen-Ortho Inc., Canada | 2004-10-01 |
| Evaluation of Efficacy and Safety of Long-acting Risperidone Microspheres in Patients With Schizophrenia or Other Psychotic Disorders When Switching From Typical Antipsychotic (Oral/Depot) or Atypical Oral Other Than Risperidone (NCT00563017) | Hospital Authority, Hong Kong | 2004-10-01 |
| A Study of the Potential Effects of Trimethoprim on the Pharmacokinetics of ER OROS Paliperidone (NCT00892541) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-10-01 |
| An Open-label Study Evaluating the Maintenance of Clinical Effect in Adult Schizophrenia Patients Switched From Risperidone Tablets to an Equivalent Dose of a Rapidly-dissolving Tablet Formulation of Risperdone (NCT00246272) | Janssen-Ortho Inc., Canada | 2004-10-01 |
| Diabetes Screening, Risk Management and Disease Management in a High-Risk Mental Health Population (NCT00253240) | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 2004-09-01 |
| Aripiprazole Open-Label, Safety and Tolerability Study (NCT00102518) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-09-01 |
| Observational Study in Patients With Schizophrenia Treated With Long-Acting Risperidone Injection (RISPERDAL CONSTA) (NCT00246194) | Janssen, LP | 2004-09-01 |
| Efficacy and Tolerability of Flunarizine for the Treatment of Schizophrenia: Comparison With Haloperidol (NCT00740259) | Ambulatório de Bipolaridade | 2004-09-01 |
| In-Patient Study In Schizophrenic Patients (NCT00197093) | GlaxoSmithKline | 2004-09-01 |
| A Study of the Efficacy and Safety of Ziprasidone in Patients With Acute Exacerbation of Schizophrenia or Schizoaffective Disorder (NCT00645229) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-09-01 |
| Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25520)(P05846) (NCT00212771) | Organon and Co | 2004-09-01 |
| Quetiapine Fumarate (SEROQUEL) Compared to Placebo in the Treatment of Adolescent Patients With Schizophrenia (NCT00090324) | AstraZeneca | 2004-09-01 |
| Treatment of Negative Symptoms of Schizophrenia With Transcranial Magnetic Stimulation (TMS) (NCT00517075) | New York State Psychiatric Institute | 2004-09-01 |
| Linear and Non-linear Analysis of EEG Changes in Schizophrenia After Atypical Antipsychotics Medication (NCT00698295) | Seoul National University Hospital | 2004-09-01 |
| Creatine Treatment in Psychiatric Disorders (NCT00140192) | Beersheva Mental Health Center | 2004-09-01 |
| Safety Study With Paliperidone ER Extended-Release (ER) Tablets in Geriatric Patients With Schizophrenia (NCT00085748) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-08-01 |
| Investigate Risperidone for the Treatment of Schizophrenia in Adolescents (NCT00088075) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-08-01 |
| A Study of the Pharmacokinetics of Paliperidone in Volunteers With Normal or Impaired Liver Function (NCT00791284) | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. | 2004-08-01 |
| The Establishment of the Early Intervention Program for Patients With Schizophrenia (NCT00172770) | National Taiwan University Hospital | 2004-08-01 |
| Evaluation of the Safety and Efficacy of Memantine as Adjunctive Treatment in Schizophrenia Patients (NCT00097942) | Forest Laboratories | 2004-08-01 |
| Fast Titration in the Treatment of Schizophrenia, Taiwan (NCT00304473) | AstraZeneca | 2004-08-01 |
| Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I Disorder (NCT00227305) | AstraZeneca | 2004-08-01 |
| Predictors of Response to Cognitive Remediation in Schizophrenia (NCT00333970) | US Department of Veterans Affairs | 2004-08-01 |
| Changes in Auditory Verbal Hallucination During Atypical Antipsychotic Treatment of Patients With Schizophrenia (NCT00328952) | Seoul National University Hospital | 2004-08-01 |
| Effect of High-Dose B-Complex Vitamins on the Symptoms of Schizophrenia (NCT00403247) | Nathan Kline Institute for Psychiatric Research | 2004-07-01 |
| Acute Psychosis Treatment in the Long Term, Unitary Group Study (APLUS) (NCT00304655) | Korea Otsuka Pharmaceutical Co., Ltd. | 2004-07-01 |
| Schizophrenia Trial of Aripiprazole (NCT00237913) | Otsuka Pharmaceutical Development & Commercialization, Inc. | 2004-07-01 |
| A Study to Compare the Efficacy and Safety of Ziprasidone and Risperidone for the Treatment of Schizophrenia in Chinese Patients (NCT00645372) | Pfizer's Upjohn has merged with Mylan to form Viatris Inc. | 2004-07-01 |
| Olanzapine Versus Aripiprazole in the Treatment of Acutely Ill Patients With Schizophrenia (NCT00103571) | Eli Lilly and Company | 2004-07-01 |
| 3-year Follow-up of Clinical Outcome After Antipsychotic Treatment Discontinuation in Psychosis Individuals (NCT02220504) | Fundación Marques de Valdecilla | 2004-07-01 |
| Comparison of Intramuscular Olanzapine and Intramuscular Haloperidol in Patients With Schizophrenia (NCT00485901) | Eli Lilly and Company | 2004-07-01 |